Shattuck Labs, Inc. Announces Initiation of Phase 1 Clinical Trial of SL-279252 (PD1/OX40L)
SL-279252 is the first Agonist Redirected Checkpoint molecule to enter clinical development from the Shattuck pipeline. AUSTIN, Texas–(BUSINESS WIRE)–Shattuck Labs,…